Royalty Pharma plc
RPRX
#713
Rank
$35.710 B
Marketcap
United States
Country
$61.80
Share price
6.94%
Change (1 day)
62.61%
Change (1 year)
Categories
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has…
Key Metrics
Trailing P/E
31.40
Forward P/E
10.18
EPS (TTM)
$1.86
Forward EPS
$5.73
Price / Book
3.81
EV / EBITDA
24.0x
Beta
0.43
Dividend Yield
1.60%
Return on Equity
13.96%
Return on Assets
5.09%
Debt / Equity
91.58
Current Ratio
2.80
Gross Margin
95.82%
Operating Margin
19.75%
Net Profit Margin
32.02%
Free Cash Flow
$-1,195,372,160
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
-5.41%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$2.378B
Latest Net Income$770.947M
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Royalty Pharma plc with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
RPRX
No recent news available. Set FINNHUB_API_KEY to enable news.
